Publications by authors named "Guang-ming Pan"
Article Synopsis
- Elevated levels of soluble stimulating factor 2 (sST2) are linked to negative outcomes in cardiovascular diseases, particularly heart failure and acute coronary syndrome, but its association with hypertensive heart disease needed further exploration.
- This study involved analyzing sST2 levels and echocardiographic data from 483 patients to investigate its relationship with left ventricular hypertrophy (LVH) and geometric remodeling in essential hypertension (EH).
- The results indicated that higher sST2 levels were significantly associated with an increased risk of LVH and concentric hypertrophy, making sST2 a promising biomarker for diagnosing and assessing risks related to hypertensive heart disease.
Article Synopsis
- Left ventricular hypertrophy (LVH) is a condition related to high blood pressure that increases the risk of serious heart issues and is influenced by factors like gender, age, and kidney function.
- A study involving 417 patients with hypertension developed a risk assessment model using clinical characteristics and biomarker data.
- The model combining both types of data (clinical and biomarkers) was the most effective, highlighting significant risk factors such as being female, overweight/obese, longer duration of hypertension, and certain biomarker levels, while better kidney function offered some protection.
Objective: To analyse the correlation between the characteristics of coronary plaque in coronary heart disease (CHD) patients with phlegm-blood stasis syndrome (PBS) and blood stasis syndrome (BSS).
Methods: Patients were divided into different groups based on Chinese medicine (CM) syndrome differentiation. The baseline demographics and clinical variables were collected from the medical records.
To analyze the medication features and the regularity of prescriptions of traditional Chinese medicine in treating patients with Qi-deficiency and blood-stasis syndrome of chronic heart failure based on modern literature. In this article, CNKI Chinese academic journal database, Wanfang Chinese academic journal database and VIP Chinese periodical database were all searched from January 2000 to December 2015 for the relevant literature on traditional Chinese medicine treatment for Qi-deficiency and blood-stasis syndrome of chronic heart failure. Then a normalized database was established for further data mining and analysis.
View Article and Find Full Text PDF[Effect of clinical pathways based on integrative medicine for patients with chronic heart failure: a multi-center research].
Zhongguo Zhong Xi Yi Jie He Za Zhi
June 2013
Objective: To assess a multi-center study effectiveness of clinical pathways based on integrative medicine (IM) for chronic heart failure (CHF) patients.
Methods: A combined method of historical control study and clinical study on concurrent control was used. After the standard management for clinical pathways was carried out in four hospitals at home, the effects on hospitalization days, medical expenses, clinical efficacy, patient satisfaction, and quality of life were assessed.
[Clinical epidemiologic investigation on Chinese medicine syndrome laws in patients with chronic heart failure].
Zhongguo Zhong Xi Yi Jie He Za Zhi
July 2011
Objective: To study the distribution laws of Chinese medicine syndromes in patients with chronic heart failure (CHF) by clinical epidemiologic investigation.
Methods: 512 CHF patients were studied, including 168 items of symptoms and 48 items of tongue and pulse pictures. A database of Chinese medicine syndromes was established, and 9 disease nature elements and 5 disease location elements were extracted.
[Double blinded randomized and controlled study on treatment of chronic heart failure by nuanxin capsule].
Zhongguo Zhong Xi Yi Jie He Za Zhi
January 2011
Objective: To evaluate the effect and safety of Nuanxin Capsule (NXC) in treating patients with chronic heart failure (CHF).
Methods: Adopting the randomized, positive controlled, double-blinded design, 150 CHF patients were assigned to the treatment group and the control group equally, they were treated with optimal western medical therapeutic scheme in combining respectively with NXC and placebo for 24 weeks. The indices for effectiveness and safety evaluation, such as Chinese medicine syndrome, grade of heart function, myocardial contraction, as well as the re-hospitalization rate and mortality, were observed.